Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial.
Anders GranholmMarie Warrer MunchSheila Nainan MyatraBharath Kumar Tirupakuzhi VijayaraghavanMaria CronhjortRebecka Rubenson WahlinStephan M JakobLuca CioccariMaj-Brit Nørregaard KjærGitte Kingo VesterlundTine Sylvest MeyhoffMarie HellebergMorten Hylander MøllerThomas BenfieldBalasubramanian VenkateshNaomi E HammondSharon MicallefAbhinav BassiOommen JohnVivekanand JhaKlaus Tjelle KristiansenCharlotte Suppli UlrikVibeke Lind JørgensenMargit SmittMorten H BestleAnne Sofie AndreasenLone Musaeus PoulsenBodil Steen RasmussenAnne Craveiro BrøchnerThomas StrømAnders MøllerMohd Saif KhanAjay PadmanabanJigeeshu Vasishtha DivatiaSanjith SaseedharanKapil BorawakeFarhad KapadiaSubhal DixitRajesh ChawlaUrvi ShuklaPravin AminMichelle S ChewChristian Aage WambergChristian GluudTheis LangeAnders PernerPublished in: Intensive care medicine (2021)
We found high probabilities of benefit and low probabilities of clinically important harm with dexamethasone 12 mg versus 6 mg daily in patients with COVID-19 and severe hypoxaemia on all outcomes up to 90 days.